Study S000752

Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00577824
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 181
Start: 2008-01
Primary completion: 2008-11
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide; DRUG:placebo
Results posted: TRUE

Registered primary outcomes

Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 [baseline, 24 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018919	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Pencek R, Postgraduate medicine	2012	Randomized trial	PMID 22913891 DOI	cites ClinicalTrials.gov:NCT00577824; registry reference DERIVED:22913891
R0018881	Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. Kadowaki T, Journal of diabetes investigation	2011	Randomized trial	PMID 24843486 DOI	cites ClinicalTrials.gov:NCT00577824; registry reference RESULT:24843486
R0026876	Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. Inagaki N, Journal of diabetes investigation	2011	Randomized trial	PMID 24843529 DOI	cites ClinicalTrials.gov:NCT00577824; registry reference RESULT:24843529